Search research articles
Contact Us
Filters
Showing results (631-640 of 686) with videos related to
Page
of 69
Sort By:
Cancer Discovery
|
February 5, 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov, Alexander Bagaev, Maria V Revuelta, et al.
The Lancet. Oncology
|
November 25, 2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, et al.
Leukemia & Lymphoma
|
July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Cancer Research
|
September 4, 2021
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
M Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
Charles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Blood
|
July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P Leonard, Marek Trneny, Koji Izutsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
John P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Page
of 69
Search research articles
Search
Showing results (631-640 of 686) with videos related to
Sort By:
Page
of 69
Cancer Discovery
|
February 5, 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov, Alexander Bagaev, Maria V Revuelta, et al.
The Lancet. Oncology
|
November 25, 2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, et al.
Leukemia & Lymphoma
|
July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.
Cancer Research
|
September 4, 2021
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
M Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
Charles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Eclinicalmedicine
|
December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
Jonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.
Blood
|
July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Deborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P Leonard, Marek Trneny, Koji Izutsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Timothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2017
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
John P Leonard, Kathryn S Kolibaba, James A Reeves, et al.
Page
of 69